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Laryngeal carcinoma is a common head and neck cancer with poor prognosis. Patients with laryngeal carcinoma usually present
late leading to the reduced treatment efficacy and high rate of recurrence. Despite the advance in the use of molecular markers for
monitoring human cancers in the past decades, there are still no reliable markers for use to screen laryngeal carcinoma and follow
the patients after treatment. Epigenetics emerged as an important field in understanding the biology of the human malignancies.
Epigenetic alterations refer to the dysregulation of gene, which do not involve the alterations of the DNA sequence. Major epigene-
tic changes including methylation imbalance, histone modification, and small RNA dysregulation could play a role in the develop-
ment of humanmalignancies. Global epigenetic change is now regarded as a molecular signature of cancer. The characteristics and
behavior of a cancer could be predicted based on the specific epigenetic pattern. We here provide a review on the understanding
of epigenetic dysregulation in laryngeal carcinoma. Further knowledge on the initiation and progression of laryngeal carcinoma at
epigenetic level could promote the translation of the knowledge to clinical use.
1. Introduction
Head and neck squamous carcinoma is estimated to be the
sixth most common malignant tumor worldwide. Of which,
laryngeal carcinoma is the second most common head and
neck squamous carcinoma [1]. According to the global can-
cer statistics in 2008, the age-standardized incidence rate
(ranged from age 0–74) is 5.5 per 100,000 in men and 0.6
per 100,000 in women in developed areas; in less developed
area, the incidence rate is 3.5 per 100,000 in men and 0.6 per
100,000 in women [2]. It is estimated that there are 12,740
new patients (male 10,160 and female 2,580, resp.) suffer-
ing from laryngeal carcinoma in the United States in 2011
(accounting for 0.7% of the total new cancer cases). It also
accounts for about 0.6% estimated cancer-related deaths in
the United States [3]. In Hong Kong, laryngeal carcinoma
took the third place in the incidence of the head and neck
cancer in 2009 [4].
Most of the laryngeal carcinoma patients are male [5].
Moreover, the majority of the patients lie in the middle-
aged group [6]. The definite cause of laryngeal carcinoma is
not yet determined, while some risk factors are believed to
be linked with the development of the disease. Tobacco and
alcohol consumption are the primary aetiologic factors [6–
8]. Chronic laryngeal inflammation induced by irritants and
prolonged voice abuse could also contribute to the develop-
ment of laryngeal carcinoma [9]. Recently, it was demon-
strated that viral infection is a plausible cause for laryngeal
carcinoma. However, the causal link betweenHPV and laryn-
geal carcinoma remains controversial. Human papilloma
virus (HPV) types 6, 11, 16, 18, and 33 are detected in
patients with laryngeal carcinoma [10]. Among all the detec-
ted HPV subtypes, the infection prevalence of HPV type 16
is much higher than the infection of the other types [11].
The link between HPV infection and laryngeal carcinoma
development is affected by geographical factor and was
confirmed in two large case-control studies [12].
Diagnosis of laryngeal carcinoma depends on the follow-
ing: symptoms (e.g., hoarseness, voice changes, and feeling
of a lump in the throat); signs (e.g., neck mass and laryn-
geal tenderness); assistant examination (including CT scan,
electronic laryngoscopic detection, and pathological biopsy)
[13]. Among these, the result of pathological biopsy, which
can supply a histological evidence, is the golden standard for
the diagnosis of laryngeal carcinoma. Histologically, most of
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the laryngeal carcinomas are squamous cell carcinoma. Mor-
phological changes including dyskeratosis, laryngeal intra-
epithelial neoplasia, atypia, and dysplasia are lesions with
high chance to transform from mild dysplasia to carcinoma
in situ [14]. In comparison, minor squamous epithelial chan-
ges such as squamous metaplasia, squamous hyperplasia,
pseudoepitheliomatous hyperplasia, keratosis, and parakera-
tosis may be found in the laryngeal region without subse-
quent malignant transformation [14].
In order to find out the definite cause of laryngeal carci-
noma and the available index for the diagnosis of this disease,
researchers put their attention on the research of molecular
markers. Since 1983, the epigenetics of human cancer draw
the researchers’ attention [15]. It is now recognized that epi-
genetic markers including hypermethylated DNA and onco-
genic microRNA could be used as screening markers for
human cancers. Further, epigenetic drugs including decita-
bine, zebularine, and TSA are under examination for use as
anticancer drug by reversing the altered epigenetic traits of
cancer cells. In comparison with the epigenetic studies in
other solid cancers, studies on laryngeal carcinoma are com-
paratively fewer. In this paper, we summarized the current
knowledge on epigenetic alterations in laryngeal carcinoma
from the published reports.
2. Epigenetic Alterations in
Human Malignancies
Wu and Morris defined epigenetics changes as “changes in
gene function that are mitotically and/or meiotically herita-
ble and that do not entail a change in DNA sequence” [16].
Thus, an epigenetic trait is developed from the epigenetic
changes in gene expression without the alteration of DNA
sequence [17]. In general, epigenetic alterations broadly
cover all the changes resulting in gene expression regulation
without interfering with the DNA sequence at genetic levels
[18]. In human cancers, common epigenetic alterations in-
clude DNA methylation, histone modification, and noncod-
ing RNA dysregulation [14, 15]. In the past decade, studies
on the abnormal epigenetic changes involved in humanmali-
gnancies are numerous leading to the development of epi-
genetic markers and therapeutic targets at epigenetic level.
2.1. Aberrant DNA Methylation Changes in Human Cancers.
In 1969, Griffith and Mahler proposed that modification of
DNA base is a possible way tomodulate gene expression [19].
In mammalian cells, modification of the cytosine residue is
the predominant DNA modification, especially in the cyto-
sine of CpG dinucleotide [20]. In human genome, the CpG
dinucleotides are particularly rich in large repetitive sequence
(e.g., centromeric repeats) and gene regulatory regions (e.g.,
CpG islands). Aberrant CpG island methylation is catalyzed
by mammalian DNA methyltransferase and is usually found
in the upstream region of the transcription start sites. CpG
island methylation could block the accessibility of transcrip-
tion factor to the promoter region of the tumor suppressor
genes [21]. Additionally, the methylated sequence itself
could recruit histone-modifying protein which induces gene
silencing by changing the chromatin structure from active
open chromatin structure to condensed closed chromatin
structure [22, 23]. Approximately, 60% of the protein-coding
genes in the human genome contain the CpG islands at their
regulatory regions [24]. In cancer cells, CpG islands become
methylated and there is de novo addition of methyl group to
the C5 position of the cytosine ring [25]. DNAmethylation is
the most studied epigenetic change in head and neck cancers.
In head and neck cancer, aberrant promoter methylation has
been found in a wide variety of genes including p14ARF, p15,
p15INK4B, p16, p16INK4A, ATM, DCC, DAPK, MINT1,
MINT2, MINT27, MINT31, RARbeta, CDH1, cyclin A1,
cytoglobin, RASSF1A, LHX6, MLH1, MGMT, and CDKN2A
[26–35]. These genes are involved in cell cycle, apoptosis,
angiogenesis, cell-cell adhesion, migration, invasion, and
metastasis [26–35]. Most of the studies focusing on the head
and neck cancers employed a collection of tissues collected
from different head and neck regions including nasopha-
rynx, oral cavity, larynx, and hypopharynx. It is difficult to
specify a methylation pattern which belongs to the laryngeal
carcinoma alone. Here, we performed a review of the methy-
lated genes with clearer association with laryngeal carcino-
mas.
2.1.1. Chromodomain-Helicase-DNA Binding Protein 5 Meth-
ylation. Chromodomain-helicase-DNA-binding protein 5
(CHD5) is involved in modifying chromatin structure.
CHD5 protein contains chromatin remodeling, helicase, and
DNA-binding motifs. Reduced CHD5 expression has been
reported in neuroblastoma [36]. Mutation of CHD5 is a rare
event. Loss of CHD5 was linked to the chromosomal deletion
on 1p36 and promoter hypermethylation in neuroblastoma
[36, 37]. Chromosomal abbreviation at 1p36 has been
reported in head and neck carcinoma [38]. Loss of heterozy-
gosity and instability of 1p36 could be detected in primary
oral and laryngeal carcinomas [39]. Although loss of CHD5
has been shown in laryngeal carcinoma, the association bet-
ween 1p36 aberrations and CHD5 loss in laryngeal carci-
noma has not yet been confirmed [40]. In laryngeal carci-
noma cell lines, CHD5 functions as growth and invasion
inhibitor [40]. CHD5 could stabilize the key regulator of
head and neck carcinoma, P53, through activating expression
of p19arf [41]. Recently, it was shown that promoter region
of CHD5 was methylated in laryngeal carcinoma cell lines
[40]. The epigenetic changes of CHD5 expression are rever-
sible by demethylating agent. Demethylation treatment of
laryngeal carcinoma cell line with 5-Aza-dC could restore
CHD5 expression [40].
2.1.2. E-Cadherin Methylation. E-cadherin (cadherin 1, type
1, E-cadherin (epithelial)) is a 97-kDa transmembrane glyco-
protein. Functional E-cadherin protein contains five extra-
cellular cadherin repeats, a transmembrane region and a
cytoplasmic tail. E-cadherin functions as adhesion protein
of epithelial cells and is involved in cell attachment and
the cell polarity and tissue architecture [42]. Loss of E-cad-
herin expression enhances head and neck cancer cell migra-
tion and increases the risk of metastasis [43]. Further, loss
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of E-cadherin could promote proliferation of head and neck
cancer cells through activating epidermal growth factor re-
ceptor (EGFR) pathways [44]. In laryngeal carcinoma, redu-
ced expression of E-cadherin has also been reported [45,
46]. Loss of E-cadherin is particularly associated with sup-
raglottic carcinoma of the larynx and is associated with the
aggressiveness of the cancers [47]. Downregulation of E-cad-
herin of supraglottic larynx carcinoma is associated with his-
tological differentiation and/or lymph nodesmetastases [48].
Loss of E-cadherin is considered as a good indication of
regional lymph node metastasis in laryngeal carcinoma pa-
tients [49–51]. In addition, the expression level of E-cadherin
is a potential indicator to predict the effect of overall treat-
ment time in patients with supraglottic carcinomas [52]. In
head and neck cancers, loss of E-cadherin in parallel with
promoter hypermethylation is frequently reported and is
suggested to be linked with the aggressive behavior of the
cancers [47, 53]. In a case control study with 235 patients
with laryngeal and hypopharyngeal cancers, E-cadherin was
reported as one of the most commonly methylated gene
in laryngeal and hypopharyngeal cancers; however, no sig-
nificant predictive value was found [54]. Recently, Marsit
et al. demonstrated that methylated E-cadherin was only
associated with head and neck patients who are light smokers
[55].
2.1.3. P16 Methylation. P16 or cyclin-dependent kinase
inhibitor 2A is a cell cycle regulator controlling G1 to G2 cell
cycle arrest. P16 could bind to cyclin-dependent kinase 4
protein (Cdk4) resulting in loss of interaction between Cdk4
and cyclin D1 leading to cell cycle arrest [56]. The expression
level of p16 is significantly reduced in laryngeal carcinoma
cells [57]. The gene encoding p16 is localized to 9p21, a
region where genetic abbreviations including LOH are fre-
quently reported [58]. It has been reported that p16 is sub-
jected to the effects of genetic and epigenetic changes such as
allelic loss, point mutations, and hypermethylation leading
to the high rate of p16 reduction in laryngeal carcinoma [58,
59]. Concurrent loss of heterozygosity and methylation of
P16 has also been reported in laryngeal carcinoma [60]. In
comparison with other inactivation mechanisms including
homozygous deletion, methylation of the promoter region,
and point mutation, p16 methylation tends to be the most
frequent inactivation pathways found in head and neck can-
cer [61]. P16 methylation is a frequent event in laryngeal car-
cinoma and was detected in more than 80% of the squamous
cell cancer of the larynx [62]. Recently, it is demonstrated
thatmethylation of p16 is an early event in squamous cell car-
cinoma at the laryngopharyngeal region, implying that me-
thylated p16 may have a clinical value in screening patients
with early laryngeal carcinoma [63]. Koscielny et al. pro-
posed that methylated p16 had prognostic value in a follow-
up period of 3 years [64].
2.1.4. DAPK Methylation. DAPK is one of the most frequ-
ently methylated genes in laryngeal carcinoma. Park et al.
demonstrated the highest methylation frequencies (87%) in
the laryngeal carcinoma tissues [65]. Similar results have
been demonstrated by Calmon et al., and they suggested
that they observed an additional correlation of methylated
DAPK1 with the lymph node metastasis [66]. Death-asso-
ciated protein kinase 1 or DAPK is a calcium/calmodulin-
dependent serine/threonine kinase involved in gamma-
interferon-induced programmed cell death. Methylation of
DAPK1 is an early event in the carcinogenesis of head and
neck cancers [67]. In lung cancers, DAPK methylation was
predominant in older patients in comparison with the young
[68]. The methylation status of the promoter region of
DAPK gene plays a significant part in controlling DAPK
transcription in laryngeal carcinoma. In laryngeal squamous
cell cancer with DAPKmethylation, DAPKmRNAwas totally
undetectable [69]; methylated DAPK could be employed to
be used as a screening marker in head and neck cancers as
it could be detected in the saliva of head and neck cancer
patients with potential value in predicting cancer recurrence
[70]. Later studies confirmed that methylated DAPK is a
good minimal invasive biomarker for head and neck cancer
screening as it is detectable in the body fluid of head and neck
cancer patients [67].
2.2. DNA Hypomethylation in Laryngeal Carcinoma Cells. As
mentioned above, focal methylation of specific tumor sup-
pressor genes is common in cancer cells. The number of me-
thylated tumor suppressor genes is higher in cancer cells in
comparison with the analogous normal counterpart. How-
ever, if we look at the density of methylated CpG dinu-
cleotides, there is a substantial reduction of 5-methylcytosine
content [71]. The global loss of genomic 5-methylcytosine
content is recognized as global hypomethylation and is
associated with the dysregulation of DNA methyltransferase
DNMT1 [72, 73]. DNMT1 is the most highly expressed
methyltransferase in somatic cells [74]. It maintains the 5-
methylcytosine patterns on the newly synthesized DNA after
cell division.
An example of hypomethylated genes in laryngeal car-
cinoma cells is S100A4. S100A4 is an acidic calcium-bind-
ing protein and functions as oncogene in a variety of human
malignancies. In oral squamous cell carcinoma, S100A4
could suppress expression of the epithelial protein E-cadhe-
rin [75]. It could also induce angiogenesis through activation
of VEGF expression in oral squamous cells [76]. Results from
animal models revealed that cancer cells with high S100A4
levels had higher metastatic rate [77]. The aggressive phe-
notype is partly contributed by the fact that S100A4 could
trigger degradation of extracelluar matrix [78]. In laryngeal
carcinoma cells, treatment with demethylating agents could
induce expression of S100A4 at both RNA and protein levels
[79].
The reasons for DNA hypomethylation remain unclear. It
is suggested that the global changes in methylation patterns
are associated with the dysregulation of the methylation
machinery. With a better understanding of the functional
role of different DNA methyltransferases, it is now proposed
that the loci-specific focal hypermethylation is linked to the
dysregulation of de novo methyltransferase 3A and 3B. On
the other hand, the global loss in methylcytosine content
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is resulting from the functional error of DNMT1. Global
hypomethylation could lead to activation of oncogenes [80].
It is now recognized that the methylation imbalance resulting
from focal methylation and global hypermethylation is the
leading cause of inactivation of tumor suppressor genes and
activation of oncogenes in cancer cells.
In laryngeal carcinoma, it has been reported that hypo-
methylation is linked to the polymorphism of the genes
regulating DNA methylation including methionine synthase
(MTR) and 5, 10-methylenetetrahydrofolate dehydrogenase,
5, 10-methenyltetrahydrofolate cyclohydrolase, 10-formyl-
tetrahydrofolate synthetase (MTHFD1), andmethylenetetra-
hydrofolate reductase (MTHFR). According to Kruszyna
et al., patients with 2756AG or GG genotypes on MTR have
a higher risk of developing laryngeal carcinoma [81].
2.3. The Role of Histone Modification in Laryngeal Carcinoma.
Histone is the structural unit of nucleosomes and is impor-
tant to the packing of DNA. Posttranslational modification of
histone (e.g., acetylation, methylation, ubiquitylation, phos-
phorylation, sumoylation, and ribosylation) could control
the activity of the surrounding DNA [82]. Modification on
histone protein could affect the protein stability, protein-
protein interaction, protein localization, and DNA binding
[83]. Laryngeal carcinoma has a higher expression level of
H3, however, the modification status of the overexpressed
histone is not yet evaluated [84]. Takahashi et al. reported
that histone H3; was overexpressed in gastric adenocarci-
noma and it was subjected to phosphorylation [85]. Asso-
ciation between histone modification (histone H3 lysine 9
methylation, H3 lysine 4 methylation, H3 lysine 9 acetyla-
tion) and the transcriptional regulation of tumor suppressor
gene is reported in laryngeal carcinoma [86]. According to
the results from Yang et al., histone modification is only a
layer of regulation. Histone modification usually works toge-
ther with other epigenetic mechanisms in controlling gene
expression [86].
2.4. Interplay between Small Noncoding RNA and Laryngeal
Carcinoma. In human genome, the protein-coding portion
is only about 2% [87]. The majority of the non-protein-
encoding portion is encoding RNA including PIWI-inter-
acting RNAs, small nucleolar RNAs, transcribed ultracon-
served regions, and large intergenic noncoding RNAs [88].
According to the size of the noncoding RNA, they could
be classified into short ncRNA, midsize ncRNA, and long
ncRNA.
2.5. Dysregulation of Short Noncoding RNA in Laryngeal
Carcinoma. PIWI-interacting RNA, transcription initiation
RNA, and microRNA are 3 major small noncoding RNA
encoded in the human genome. PIWI-interacting RNA (26–
31 bp) was discovered in 2006 and functions through inter-
acting with the Argonaute family protein PIWI [89]. PIWI-
interacting RNA could control gene expression by modula-
ting locus-specific methylation [90]. However, its role in
human cancers remains to be elucidated. Transcription ini-
tiation RNA controls gene expression at postinitiation stage
of transcription [91]. It is evolutionarily conserved and is
associated with the chromatin state [92].
2.5.1. Candidate Tumor-Suppressing MicroRNA in Laryngeal
Carcinoma. In comparison with the other 2 small noncoding
RNAs, the pathway of microRNA biogenesis and func-
tion in human cancers is much clearer. MicroRNA is small
noncoding RNA that regulates gene expression at posttrans-
criptional level [93]. Mature microRNAs are short single-
stranded molecules, which are about 22 nucleotides long.
They function by directly interfering with the target mRNA
sequence through complementary interaction. The binding
of the microRNA to the 3′UTR of the target mRNA will hin-
der the subsequent translation process or promote cleavage
of the target mRNA [94]. It is estimated that microRNA is
involved in the control of about 60% protein-coding genes
[89].
Head and neck cancer has a distinctive microRNA exp-
ression in comparison with their normal counterpart, and
the microRNA expression is suggested to play a significant
part in the pathogenesis of head and neck cancer [95].
In laryngeal carcinoma, microRNA could be classified into
oncogenic microRNA and tumor suppressing microRNA
[96]. Tumor-suppressing microRNA should target oncogene
under normal circumstance. Lujambio et al. demonstra-
ted that loss/suppression of tumor-suppressing microRNA
would promote cancer progression because of the elevation
in target oncogene expression [97].
Let-7. Let-7 was discovered in 2000 and is one of the well-
studied tumor suppressing microRNAs [98]. Let-7 is a family
of microRNA including let-7a, let-7b, let-7c, let-7d, let-7e,
let-7f, let-7 g, let-7i, let-7b∗, let-7e∗, and microRNA-98 [99].
Expression changes of let-7 family member have been repor-
ted in numerous human cancers suggesting that the let-7
isoform is playing a distinctive function in different cancers.
Let-7a could repress RAS and/or c-MYC expression in
human cancer cells, and such effects are demonstrated in
laryngeal carcinoma recently [100, 101]. Let-7a could sen-
sitize chemoresistant head and neck cancer cells through
modulating stemness genes [102]. Let-7d facilitates the deve-
lopment of epithelial-mesenchymal transition (EMT) traits
in oral squamous cell carcinoma [103]. In laryngeal carci-
noma, let-7 is a growth inhibitor and could induce apoptosis
in laryngeal carcinoma cells [100]. Further, let-7 expression
is linked to the sensitivity of cancer cells to radio- and/or
chemotherapy [104]. It is noted that not all the let-7 family
members are downregulated in cancer cells. Let-7i is prefe-
rentially upregulated in laryngeal carcinoma, albeit the func-
tional significance remains unclear [105].
MicroRNA-7. MicroRNA-7 is a proliferation suppressor
[106]. There are reports suggesting that microRNA-7 sup-
pression leads to the upregulation of epidermal growth
factor receptor expression [107]. Webster et al. confirm the
association, and they observed that microRNA 7 is linked to
cell cycle progression and cell viability [108]. In vivo studies
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demonstrated that microRNA-7 is suppressed by inflamma-
tory response [109]. In addition, increasing microRNA-7 in
cancer cell line through liposomal delivery could inhibit cell
division and is suggested to be a potential treatmentmodality
[110]. In head and neck cancer, let-7 insulin-like growth
factor 1 receptor (IGF1R) pathway is possibly linked with
cancer cell migration and invasion [111]. MicroRNA-7 is
a candidate therapeutic agent in laryngeal carcinoma as it
could enhance the sensitivity of cancer cells to radiotherapy
[112].
MicroRNA-206. Downregulation of microRNA-206 has
been reported in breast carcinoma, leiomyoma, lung carci-
noma, renal cell carcinoma, and rhabdomyosarcomas [113–
117]. In laryngeal carcinoma tissues, microRNA-206 expres-
sion was significantly reduced in comparison with the
normal laryngeal tissues [118, 119]. Zhang et al. demons-
trated that the expression levels of miR-206 are associated
with the T grade, nodal metastasis and clinical stage of pa-
tients with laryngeal carcinoma [118]. MicroRNA-206 con-
trols the expression of vascular endothelial growth factor
(VEGF) in laryngeal cancer cells. VEGF is a prognostic indi-
cator of laryngeal carcinoma and is correlated with tumor
size and lymph node metastasis [118, 120]. Liu et al. show
that miR-206 controls cell migration and invasion through
modulating the actin cytoskeleton [121]. MicroRNA-206
could induce apoptosis and inhibit the antiapoptotic path-
ways such as notch3 [113]. Taken together, miR-206 is sug-
gested to be a candidate tumor-suppressing microRNA in
human cancers.
2.5.2. Candidate Oncogenic MicroRNA in Laryngeal Carci-
noma. In laryngeal carcinoma, studies on tumor-suppres-
sing microRNA are comparably more than the oncogenic
microRNA. One representative example of the oncogenic
microRNA identified in laryngeal carcinoma is microRNA-
21. MicroRNA-21 upregulation was first reported in human
glioblastoma in 2005 [122]. Overexpression of microRNA-
21 has been reported in numerous human malignancies sug-
gesting its importance in the genesis of cancer. MicroRNA-21
overexpression is associated with cancer at advanced stages
and might have both diagnostic and prognostic values [123–
125]. Suppressing microRNA-21 expression in laryngeal car-
cinoma cell could induce apoptosis and prevent cancer cell
invasion by inducing cell cycle arrest [126].
2.5.3. Tumor-Suppressing MicroRNA in Laryngeal Carci-
noma—Loss through DNA Methylation. MicroRNA is a
kind of epigenetic regulator. MicroRNA itself however is
also controled by epigenetic mechanisms including DNA
methylation.
Methylated MicroRNA-9. According to microRNA registry
miRBase (http://www.mirbase.org/), microRNA 9 has 3 iso-
forms. They are hsa-mir-9-1 (MI0000466), hsa-mir-9-2 (MI-
0000467), and hsa-mir-9-3 (MI0000468). In oral and oral
pharyngeal carcinoma, microRNA-9 is a candidate tumor
suppressor and could control cell proliferation through
regulating the PTEN pathway. MicroRNA-9 methylation has
recently been reported in oral pharyngeal carcinoma includ-
ing laryngeal carcinoma [127]. Methylated microRNA-9
could differentiate laryngeal cancer from adjacent histolog-
ically normal tissues with high specificity (ranging from 97
to 100%).
Methylated MicroRNA-137. Downregulation of microRNA-
137 has been reported in head and neck malignancies [128].
The association between microRNA-137 downregulation
andmicroRNA-137methylation has been reported in a num-
ber of solid cancers including head and neck squamous cell
carcinoma [129]. Head and neck squamous cell carcinoma
patients with methylated microRNA-137 have poor survival
rate [129]. In glioblastoma multiforme cells, expression of
microRNA-137 could inhibit cancer cell proliferation [130].
Downregulation of microRNA-137 by DNA methylation is
an early event in colorectal cancer [131]. Balaguer suggested
that methylated microRNA-137 might have a therapeutic use
as reverse expression of microRNA-137 in colorectal cancer
cell could inhibit proliferation of colorectal cancer cells
[131]. In laryngeal carcinoma, however, the functional roles
of microRNA-137 remained to be elucidated.
2.5.4. Midsize Noncoding RNA Associated with Laryngeal Car-
cinoma. Small nucleolar RNA is involved in themodification
and stability of ribosomal RNA [132]. Although its function
remains to be clarified, differential expression of small nuc-
leolar RNA is observed in non-small-cell lung cancer and
could be employed in cancer screening. In addition, the
highly expressed small nucleolar RNA could be detected in
the peripheral blood of cancer patients suggesting that it may
be useful to be used as a kind of molecular marker for cancer
patients [133]. Recently, Mirisola et al. performed a genome-
wide gene expression profiling of 20 laryngeal carcinoma
and showed that 2 small noncoding RNAs, SNORA16A and
SNORD14C, were associated with the risk of laryngeal carci-
noma development [134].
3. Conclusion
Increasing evidence suggests that epigenetic alteration is
playing a critical part in the development of head and neck
carcinoma. In comparison with squamous cell carcinoma of
other head and neck regions, studies on the epigenetic dys-
regulation on laryngeal carcinoma are relatively fewer and
most studies focused on a few of the epigenetic changes in
their sample group. With the recent advance in technology
such as next-generation sequencing and microarray (e.g.,
methylation array and microRNA array), we could foresee
that epigenetic studies on laryngeal carcinoma will change
from candidate gene approach to global high-throughput
profiling. This provides an opportunity to explore and dissect
the disease from different perspectives. More importantly,
suitable epigenetic markers could be identified through the
gaining understanding of the disease.
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